In epidermal growth factor 2 (HER-2)-positive breast cancer patients treated with trastuzumab, the incidence of myocardial injury was reduced in carriers of the UGT2B7-161 (rs7668258) T allele (45). This evidence concerns the gene ERBB2 and breast carcinoma.